Scholars Central

Conference abstractPublished 23 Sep 2013

Trial designs for biosimilars development

Authors: Russell Reeve

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In February 2012, the FDA issued guidance documents for the development of biosimilars, including scientific considerations. However, the exact details of what clinical trial designs will meet Agency scrutiny regarding bioequivalence have not been publicly disclosed. The FDA appears to be taking a ?wait and see? approach as to what acceptable study designs may look like for biosimilar products to garner approval. In this talk, we discuss several trial design options for both Phase I and Phase III. Many options are available to the trial designer, including choice of endpoints, time on study, fixed design or adaptive (e.g., group sequential), single dose or multiple dose. For each phase, we discuss several of the more common design choices, the effect of the design on statistical considerations and power, and different options that appear to have acceptance. Finally, we mention the effect of design on site and country selection.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Russell Reeve”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels